Perspectives
that Matter to You
Apr 09, 2025
SUBROGEES BEWARE—YOU CAN BE COMPELLED TO ARBITRATE AS THIRD-PARTY BENEFICIARIES TO AN ARBITRATION AGREEMENT
By Miguel J. Chamorro Cases requiring non-signatories to an arbitration agreement to arbitrate are not uncommon. Cases compelling subrogees to arbitrate, not because of an insurance policy but because of […]
READ MORE
Jan 24, 2025
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the […]
READ MORE
Jan 24, 2025
Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders
By Nicole DeFeudis November 22, 2024 Eli Lilly and Novo Nordisk have filed dozens of lawsuits against compounding pharmacies marketing their own versions of popular weight loss and diabetes drugs. […]
READ MORE
LOAD MORE
Apr 09, 2025
SUBROGEES BEWARE—YOU CAN BE COMPELLED TO ARBITRATE AS THIRD-PARTY BENEFICIARIES TO AN ARBITRATION AGREEMENT
By Miguel J. Chamorro Cases requiring non-signatories to an arbitration agreement to arbitrate are not uncommon. Cases compelling subrogees to arbitrate, not because of an insurance policy but because of […]
READ MORE
Jan 24, 2025
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the […]
READ MORE
Jan 24, 2025
Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders
By Nicole DeFeudis November 22, 2024 Eli Lilly and Novo Nordisk have filed dozens of lawsuits against compounding pharmacies marketing their own versions of popular weight loss and diabetes drugs. […]
READ MORE
Jan 21, 2025
THE ROLE OF DELEGATION CLAUSES IN MOTIONS TO COMPEL ARBITRATION WHEN YOUR FAMILY MEMBER SIGNS AN ARBITRATION AGREEMENT
It happens every so often: someone signs an agreement to arbitrate legal claims, the agreement has a solid clause delegating arbitrability issues to an arbitrator, and then a member of […]
READ MORE
Jan 21, 2025
Florida Civil Litigation Update: Major changes to the rules of civil procedure have gone into effect. Practitioners must be aware of the consequences for noncompliance.
January 1, 2025, marked a historic day for Florida civil litigation as the much-anticipated sweeping changes to the Florida Rules of Civil Procedure went into effect. These changes will fundamentally […]
READ MORE
Jan 14, 2025
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her Endpoints News story about the case. Lilly’s lawsuit, filed […]
READ MORE
Dec 20, 2024
FDA Issues Five Warning Letters to Makers of Knockoff GLP-1 Drugs
On December 17, 2024, the FDA published five (5) warning letters previously issued to makers of knockoff GLP-1 drugs. Four of the five warning letters were to companies (specifically, Xcel […]
READ MORE
Nov 04, 2024
COMPOUNDED GLP-1 DRUGS: IS THE PARTY OVER? THESE ARE THE LEGAL AND REGULATORY ISSUES FOR GAME CHANGING WEIGHT LOSS PRODUCTS AND THE COMPANIES SELLING THEM
Glucagon-like peptide-1, or “GLP-1” drugs, such as Ozempic® and Mounjaro®, have exploded in popularity in the United States for weight management and the treatment of obesity. However, GLP-1 drugs were […]
READ MORE
Nov 04, 2024
COMPOUNDED GLP-1 DRUGS: IS THE PARTY OVER? THESE ARE THE LEGAL AND REGULATORY ISSUES FOR GAME CHANGING WEIGHT LOSS PRODUCTS AND THE COMPANIES SELLING THEM
Author’s Note: This is an updated version of the post to our blog dated October 30, 2024. Later that day, FDA announced the resolution of Novo Nordisk’s semaglutide shortage, which […]
READ MORE
